Aizong Shen

17 Lujiang Road
Hefei, 230001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.

Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.

Journal: PharmacoEconomics - open

Published: November 29, 2025

Pharmacokinetics and safety study of methylphenidate hydrochloride sustained-release tablets in Chinese healthy participants.

Pharmacokinetics and safety study of methylphenidate hydrochloride sustained-release tablets in Chinese healthy participants.

Journal: Journal of pharmaceutical sciences

Published: November 20, 2025

Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.

Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 10, 2025

Platinum(IV) Prodrug with a Docosahexaenoic Acid Ligand Preferentially Accumulates in Drug-Resistant Cells and Triggers Ferroptosis to Overcome Drug Resistance.

Platinum(IV) Prodrug with a Docosahexaenoic Acid Ligand Preferentially Accumulates in Drug-Resistant Cells and Triggers Ferroptosis to Overcome Drug Resistance.

Journal: Journal of medicinal chemistry

Published: June 17, 2025

Health-related quality of life and financial toxicity in Chinese patients with multiple myeloma: a two-year real-world multicentre study.

Health-related quality of life and financial toxicity in Chinese patients with multiple myeloma: a two-year real-world multicentre study.

Journal: Health and quality of life outcomes

Published: June 05, 2025

Adebrelimab versus serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.

Adebrelimab versus serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.

Journal: International journal of technology assessment in health care

Published: December 01, 2024

A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.

A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.

Journal: Advances in therapy

Published: August 08, 2024

Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective.

Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective.

Journal: Health economics review

Published: December 19, 2023

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial.

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial.

Journal: Investigational new drugs

Published: July 19, 2023

TMAO Promotes NLRP3 Inflammasome Activation of Microglia Aggravating Neurological Injury in Ischemic Stroke Through FTO/IGF2BP2.

TMAO Promotes NLRP3 Inflammasome Activation of Microglia Aggravating Neurological Injury in Ischemic Stroke Through FTO/IGF2BP2.

Journal: Journal of inflammation research

Published: November 29, 2022

Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective.

Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective.

Journal: Frontiers in oncology

Published: October 13, 2022

Protein encapsulation of nanocatalysts: A feasible approach to facilitate catalytic theranostics.

Protein encapsulation of nanocatalysts: A feasible approach to facilitate catalytic theranostics.

Journal: Advanced drug delivery reviews

Published: September 29, 2022

Showing 1-12 of 46

Last Updated: 09/26/2026